



Staging of Testicular Cancer

Jodi K. Maranchie, MD FACS University of Pittsburgh






Developed through generous support from the American Cancer Society.



Stage of Testicular Cancers









Testicular Cancer



- More than 99% arise from germ cells
- <1% of all cancers in males</p>
- Early age at presentation common
- Undescended (cryptorchid) testes predisposed to cancer
- Germ cell neoplasia in situ is a precursor





Tumors included



Staging applies to:

- Germ cells tumors
- Leydig cell tumors—malignant only
- Sertoli cell tumors—malignant only
- Sex cord-stromal tumors

Not included:

- Spermatocytic tumors
- paratesticular neoplasms
- hematolymphoid tumors (staged elsewhere)
- Non-malignant stromal tumors
- prepubertal germ cell tumors








Histologic Subtypes





- Seminoma (A)
- Non-seminoma (NSGCT)
 - Embryonal cell (B)
 - Teratoma (C)
 - Choricarcinoma (D)
 - Yolk sac tumor (E)
 - Seminoma (A)














Features specific to testis cancer staging




- Addition of serum markers as a separate staging category (TNMS)
- No Stage IV disease (IIIC is the highest)
- Tumor grade not included






Testicular Development and Migration












Testicular Canner "Landing Zones"



QUALITY PROGRAMS
of the AMERICAN COLLEGE
OF SURGEONS


PROGRAMS




Changes to pT stage 8th Edition



- Tumor size has prognostic significance for Seminoma
- pT1 subdivided into
 - pT1a <3cm
 - -pT1b < 3cm
- Maximal diameter of largest lesion
- Applicable to pure seminoma only.






BMC Urology 20(127), 2020



Changes to pT stage 8th Edition



- Invasion into the epididymis has been upstaged to pT2
- Reflects progression beyond the vascular hilum or through the tunica albuginea




pT2



Changes to pT stage 8th Edition



- Soft tissue invasion of the testicular hilum has specifically addressed as stage pT2
- Prevent confusion with spermatic cord involvement.
- Spermatic cord (pT3) defined as "tumor extending beyond the angle between the epididymis and cord"






pT staging



- Determined by pathology, not imaging
- pT1
 - Confined to testis including Rete Testis
 - No lymphovascular invasion
- pT2
 - Lymphovascular invasion
 - Invasion tunica albuginea (outer layer)
 - Invasion epididymis
 - Invasion hilar soft tissue
 - Intravascular-only spermatic cord involvement







pT Category



- pT3
 - Invasion of spermatic cord stroma
 - Continuous only
- pT4
 - Invasion of the scrotal wall







Serum Markers



- Alpha fetoprotein (AFP)
 - half-life 5-7 days
 - 60% non-seminomas
 - Never expressed by pure seminoma
- Beta human chorionic gonadotropin (BHCG)
 - Half-life 36-48 hours
 - 40% non-seminomas
 - 15% seminomas
- Lactate dehydrogenase
 - Non-specific
 - Correlate with tumor burden





IGCCCG Risk Stratification



Prognosis	Serum Markers	5-year Survival
Good	LDH < 1.5 x normal hCG < 5,000 AFP <1,000	90% S1
Intermediate	LDH 1.5-10 x normal OR hCG 5,000-50,000 OR AFP 1,000-10,000	75% S2
Poor	LDH > 10 x normal hCG > 50,000 AFP > 10,000	45% S3



Marker Trends



- Should be drawn <u>before and after</u> orchiectomy.
- Monitored over time for predicted decline
- Assign S-stage if:
 - do not normalize as expected or
 - begin to rise





N Category



pN Category	Criteria		
pNx	Not assessed		
pN0	No regional lymph node metastasis		
pN1	5 or fewer nodes, all less than 2cm		
pN2	>5 nodes OR any node >2 but <5cm		
pN3	Any node >5cm		



M Category



pM Category	Criteria		
pM0	No distant metastases		
pM1a	Non-regional lymph nodes or pulmonary metastases		
pM1b	Non-pulmonary visceral metastases		



AJCC Prognostic Stage Groups



- Stage I
 - No lymph nodes or mets
- Stage IS
 - Elevated/rising markers in the absence of clinical disease (any S)
- Stage II
 - Any N with S0-1
- Stage III
 - Any M OR
 - Any S > 1

		Stage Grouping		
Stage	Т	N	М	S
Stage I	pT1-4	N0	MO	SX
IA	pT1	N0	MO	S0
IB	pT2	N0	MO	S0
	рТ3	N0	MO	S0
	pT4	N0	MO	S0
IS	Any pT	N0	МО	S1-3
Stage II	Any pT	N1-3	МО	SX
IIA	Any pT	N1	МО	S0-1
IIB	Any pT	N2	MO	S0-1
IIC	Any pT	N3	МО	S0-1
Stage III	Any pT	Any N	M1	SX
IIIA	Any pT	Any N	M1a	S0-1
IIIB	Any pT	N1-3	MO	S2
	Any pT	Any N	M1a	S2
IIIC	Any pT	N1-3	МО	S3
	Any pT	Any N	M1a	S3
	Any pT	Any N	M1b	Any S





- 24 y/o male, scrotal mass
- AFP 146, hCG 15, LDH<1.5 x ULN
- CT chest and abdomen normal
- Orchiectomy
 - 3.5 cm tumor confined within tunica albuginea, involving rete testis
 - Lymphovascular invasion seen
 - Histology pure seminoma
- Markers 5 weeks later: AFP 5, hCG 1, LDH normal



Case 1



Stage Grouping				
Stage	Т	N	M	S
Stage I	pT1-4	N0	MO	SX
IA	pT1	N0	MO	S0
ΙΒ	pT2	N0	MO	S0
	рТО	NO	MO	<u>60</u>
	pT4	N0	МО	S0
IS	Any pT	N0	МО	S1-3
Stage II	Any pT	N1-3	МО	SX
IIA	Any pT	N1	MO	S0-1
IIB	Any pT	N2	MO	S0-1
IIC	Any pT	N3	МО	S0-1
Stage III	Any pT	Any N	M1	SX
IIIA	Any pT	Any N	M1a	S0-1
IIIB	Any pT	N1-3	MO	S2
	Any pT	Any N	M1a	S2
IIIC	Any pT	N1-3	MO	S3
	Any pT	Any N	M1a	S3
	Any pT	Any N	M1b	Any S

- pT2cN0cM0

 - S0





- 39 y/o male with back and abdominal pain and weight loss
- AFP 277, hCG >200,00, LDH 573
- CT chest and abdomen and pelvis:
- 12 cm interaorto-caval mass
- Bilateral pulmonary nodules






Right Orchiectomy

- 0.9 cm tumor, involving hilar soft tissue
- No lymphovascular invasion
- Histology 99% teratoma, 1% seminoma)

Summary:

- pT2 (hilar soft tissue invasion)
- cN3 (>5cm regional nodes)
- cM1a (pulmonary only)
- -S3 (hCG > 50,000)



Scrotal ultrasound right testis



Case 2



Stage Grouping				
Stage	Т	N	M	S
Stage I	pT1-4	N0	MO	SX
IA	pT1	N0	MO	S0
IB	pT2	N0	MO	S0
	рТ3	N0	МО	S0
	pT4	N0	МО	S0
IS	Any pT	N0	МО	S1-3
Stage II	Any pT	N1-3	MO	SX
IIA	Any pT	N1	МО	S0-1
IIB	Any pT	N2	MO	S0-1
IIC	Any pT	N3	МО	S0-1
Stage III	Any pT	Any N	M1	SX
IIIA	Any pT	Any N	M1a	S0-1
IIIB	Any pT	N1-3	MO	S2
	Any pT	Any N	M1a	S2
IIIC	Any pT	N1-3	MO	S3
	Any pT	Any N	M1a	S3
	Arry pT	Arry N	M15	Any C

- pT2cN3
- cM1a
- S3



Questions or Comments?



Thank you!

Submit questions to AJCC Forum: http://cancerbulletin.facs.org/forums/

or

Jodi Maranchie: maranchiejk@upmc.edu

